© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
September 18, 2021
Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.
July 16, 2021
Singh highlights the phase 3 INTACT trial, which is comparing the safety and efficacy of standard chemoradiation alone versus chemoradiation plus atezolizumab in patients who received TURBT.